Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 501–600 of 1,002
Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis
Oh, S. J., Cho, H., Kim, S., Noh, K. H., Song, K., Lee, H.-J., Woo, S. R., Kim, S., Choi, C. H., Chung, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2325 · Cited by 46
“Notably, targeting of Cyclin D1-CDK4/6 has already been shown to cause a statistically significant improvement in progression-free survival in breast cancer (19-21).”
BackgroundThe Breast Cancer Therapy Expert Group (BCTEG), Abraham, J., Coleman, R. E., ELIAS, A. D., Holmes, F. A., Kalinsky, K. M., Kittaneh, M., Lower, E. E., Mahtani, R. L., Mamounas, E., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4783-1 · Cited by 45
Personalizing aromatase inhibitor therapy in patients with breast cancer
Hamadeh, I. S., Patel, J. N., Rusin, S., & Tan, A. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.014 · Cited by 46
Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
Ettl, J. (2019) · Breast Care · doi:10.1159/000499534 · Cited by 52
Wilkie, J., Schickli, M. A., Berger, M. J., Lustberg, M. B., Reinbolt, R. E., Noonan, A. M., Ramaswamy, B., Sardesai, S. D., VanDeusen, J. B., Wesolowski, R., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.010 · Cited by 45
Posocco, B., Buzzo, M., Poetto, A. S., Orleni, M., Gagno, S., Zanchetta, M., Iacuzzi, V., Guardascione, M., Puglisi, F., Basile, D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228822 · Cited by 48
Beddok, A., Xu, H. P., Henry, A. A., Porte, B., Fourquet, A., Cottu, P. H., & Kirova, Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0957-9 · Cited by 46
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 47
Xie, W., Zhao, H., Wang, F., Wang, Y., He, Y. Z., Wang, T., Zhang, K., Yang, H., Zhou, Z., Shi, H., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01800-x · Cited by 49
Kraus, A. L., Yu‐Kite, M., Mardekian, J., Cotter, M. J., Kim, S., Decembrino, J., Snow, T., Carson, K. R., Rockland, J. M., Gossai, A., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2454 · Cited by 47
“Additionally, in the current study, real- world response was evaluated based on clinical assessment and radiologist notes, whereas the palbociclib phase III clinical trials assessed tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.(9,11) However, an analysis of female pati…”
MethodSelf-citationNabieva, N., & Fasching, P. A. (2021) · Cancers · doi:10.3390/cancers13225643 · Cited by 46
“ET +/− palbociclib PALOMA-2 [66] 666 2:1 24.”
Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
Pennycook, B. R., & Barr, A. R. (2021) · Open Biology · doi:10.1098/rsob.210125 · Cited by 49
“…cancer, and their use in the treatment of other cancers is an area of active investigation (Álvarez-Fernández & Malumbres, 2020; Dickler et al., 2017; Finn et al., 2016; Fry et al., 2004; Gelbert et al., 2014; Hortobagyi et al., 2016; Rader et al., 2013; Sledge et al., 2017; Tripathy et al., 2017).”
BackgroundBreast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 51
Abdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 50
Role of senescence induction in cancer treatment
Qin, S., Schulte, B. A., & Wang, G. Y. (2018) · World Journal of Clinical Oncology · doi:10.5306/wjco.v9.i8.180 · Cited by 45
Yu, Z., Zhan, C., Du, H., Zhang, L., Liang, C., & Zhang, L. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03739-1 · Cited by 48
Mayer, E. L., Fesl, C., Hlauschek, D., Garcia-Estevez, L., Burstein, H. J., Zdenkowski, N., Wette, V., Miller, K. D., Balic, M., Mayer, I. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01918 · Cited by 44
Self-citationLauro, V. D., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Mastro, L. D., Giuliano, M., Puglisi, F., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100629 · Cited by 47
“The phase III PALOMA-2 study recruited postmenopausal women who had not received prior systemic therapy for HRþ/HER2 aBC and randomized them to palbociclib or placebo plus letrozole.(24) In this study the FACT-B and EQ-5D questionnaires were used.”
MethodRecurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Pineda, E., Doménech, M., Hernández, A., Comas, S., & Balañá, C. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s366371 · Cited by 48
Colón‐Otero, G., Weroha, S. J., Foster, N. R., Haluska, P., Hou, X., Wahner-Hendrickson, A. E., Jatoi, A., Block, M. S., Dinh, T. A., Robertson, M. W., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.020 · Cited by 44
Brufsky, A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.004 · Cited by 50
Bilgin, B., Şendur, M. A. N., Dede, D. Ş., Akıncı, M. B., & Yalçın, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1348344 · Cited by 48
Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas
Richardson, T. E., Sathe, A. A., Kanchwala, M., Jia, G., Habib, A. A., Xiao, G., Snuderl, M., Xing, C., & Hatanpaa, K. J. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly026 · Cited by 48
Shatsky, R. A., Parker, B. A., Bui, N. Q., Helsten, T. L., Schwab, R. B., Boles, S. G., & Kurzrock, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1038 · Cited by 45
Feng, W. W., & Kurokawa, M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.100 · Cited by 49
“8 months in patients with advanced ER +HER2− breast cancer[58].”
BackgroundLi, J., Fu, F., Yu, L., Huang, M., Lin, Y., Mei, Q., Lv, J., & Wang, C. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05528-2 · Cited by 47
Ettl, J., Im, S., Ro, J., Masuda, N., Colleoni, M. A., Schnell, P., Bananis, E., Lu, D. R., Cristofanilli, M., Rugo, H. S., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01263-0 · Cited by 45
“The pooled population included a total of 875 patients who received palbociclib plus ET (PALOMA-1, n = 84; PALOMA-2, n = 444; PALOMA-3, n = 347) [3, 4, 6].”
Self-citationMechanisms of endocrine resistance in hormone receptor-positive breast cancer
Gao, Y., Yu, Y., Zhang, M., Yu, W., & Kang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1448687 · Cited by 50
The emerging role of CDK4/6i in HER2-positive breast cancer
O'Sullivan, C. C., Suman, V. J., & Goetz, M. P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919887665 · Cited by 46
Campos, J. F., Besson, T., & Raboin, S. (2022) · Pharmaceuticals · doi:10.3390/ph15030352 · Cited by 45
“The results of post-marketing reports and electronic health records, updated in April 2019, show its safety and clinical efficacy [34,35].”
BackgroundLi, X., Seebacher, N. A., Garbutt, C., Ma, H., Gao, P., Xiao, T., Hornicek, F. J., & Duan, Z. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0474-4 · Cited by 41
Tang, S., Sethunath, V., Metaferia, N. Y., Nogueira, M. F., Gallant, D. S., Garner, E. R., Lairson, L. A., Penney, C. M., Li, J., Gelbard, M. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110417 · Cited by 46
Li, Z., Song, Z., Hong, W., Yang, N., Wang, Y., Jian, H., Liang, Z., Hu, S., Peng, M., Yu, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01897-y · Cited by 48
“15,16 22 However, anti-HER2 mAb monotherapy had consistently demonstrated limited antitumor activity for HER2 -altered NSCLC. 23,24 Recently, the advent of antibody-drug conjugates (ADC), a class of therapeutic compounds designed to deliver cytotoxic agents selectively to tumor cells, has renewed…”
BackgroundRamos-Esquivel, A., Hernández-Steller, H., Savard, M.-F., & Landaverde, D. (2018) · Breast Cancer · doi:10.1007/s12282-018-0848-6 · Cited by 44
“5 mg/day in the PALOMA-2 and MONALEESA-2 trials, respectively [15, 16].”
Targeting forkhead box M1 transcription factor in breast cancer
O'Regan, R. M., & Nahta, R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.05.019 · Cited by 43
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
Palumbo, A., Lau, G., & Saraceni, M. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018795146 · Cited by 45
Messer, J. A., Ekinci, E., Patel, T. A., & Teh, B. S. (2019) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2019.03.001 · Cited by 42
“J Neurooncol 2012;111(2):113–21, http://dx.”
Tibes, R., & Bogenberger, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01205 · Cited by 44
Grande, E., Teulé, À., Alonso‐Gordoa, T., Jiménez‐Fonseca, P., Benavent, M., Capdevila, J., Custodio, A., Vera, R., Munárriz, J., Casta, A. L., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0033 · Cited by 44
“Palbociclib (Ibrance, Pfizer) received accelerated approval in 2015 by the US Food and Drug Administration, in combination with letrozole, for the treatment of hormone receptor-positive, human epidermal growth factor receptor (HER2)-negative advanced breast cancer after endocrinebased therapy [17, 18].”
BackgroundXi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 47
Dhakal, A., Thomas, R. A., Levine, E. G., Brufsky, A., Takabe, K., Hanna, M. G., Attwood, K. M., Miller, A., Khoury, T., Early, A., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420944864 · Cited by 46
“Median diseasefree interval (duration between diagnosis of primary breast cancer and the recurrence) was 60 months (4, 276).”
BackgroundZhang, Y., Ma, Z., Sun, X., Feng, X., & An, Z. (2022) · The Breast · doi:10.1016/j.breast.2022.02.011 · Cited by 46
“Methods: Electronic databases and ClinicalTrials.gov were searched from inception to October 1, 2021 for RCTs reporting the occurrence of LD/pneumonitis in cancer patients treated with CDK4/6 inhibitors.”
BackgroundInfluentialMittal, A., Moltó, C., Tamimi, F., Schlam, I. M., Sammons, S. L., Tolaney, S. M., & Tarantino, P. (2023) · Cancers · doi:10.3390/cancers15072015 · Cited by 43
Bansal, I., Pandey, A. K., & Ruwali, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1244597 · Cited by 44
“Several clinical trials have demonstrated a considerable therapeutic advantage for the use of CDK4/ 6 inhibitors, like palbociclib, in the treatment of advanced breast cancer that is hormone receptor-positive but HER2-negative (Finn et al., 2016).”
BackgroundMethodInfluentialStanciu, I.-M., Paroșanu, A. I., & Niţipir, C. (2023) · Biomolecules · doi:10.3390/biom13091422 · Cited by 48
“In patients taking palbociclib with letrozole, the most often reported grade 3 AEs (5%), in decreasing order, were neutropenia, leukopenia, infections, and anemia [27,28].”
BackgroundTommasi, C., Airò, G., Pratticò, F., Testi, I., Corianò, M., Pellegrino, B., Denaro, N., Demurtas, L., Dessì, M., Murgia, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071873 · Cited by 47
“The introduction of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6Is) in combination with ET is the standard treatment for advanced HR-positive/HER2-negative disease [70–72] and preclinical data suggest that CDK4/6I are active also in HER2-positive cell lines [73,74].”
BackgroundNguyen, L. V., Searle, K., & Jerzak, K. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27238 · Cited by 41
“Among trials evaluating the efficacy of CDK4/6 inhibitors in patients with treatment-naïve HR+/HER2advanced breast cancer, only PALOMA-2 included patients with brain metastases (2 of 666 enrolled participants), but only if they were previously treated and stable.”
BackgroundInfluentialCDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 43
Tolaney, S. M., Im, Y.-H., Calvo, E., Lu, Y.-S., Hamilton, E., Forero-Torres, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0645 · Cited by 39
Smyth, L. M., Batist, G., Meric‐Bernstam, F., Kabos, P., Spanggaard, I., Lluch, A. M., Jhaveri, K. L., Varga, A., Wong, A., Schram, A. M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00251-7 · Cited by 43
Dominguez-Cejudo, M. A., Gil-Torralvo, A., Solís, M. C., Molina‐Pinelo, S., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316771 · Cited by 45
“These drugs are approved based on data from randomized clinical trials in both adjuvant [87–90] and metastatic settings [91–93], as well as in combination with other drugs like CDK4/6 inhibitors [94–96], olaparib [97], or everolimus [98], with similar efficacy and toxicity.”
BackgroundSeize the engine: Emerging cell cycle targets in breast cancer
Fuentes‐Antrás, J., Bedard, P. L., & Cescon, D. W. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1544 · Cited by 42
Reinert, T., & Barrios, C. H. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728928 · Cited by 47
Profile of abemaciclib and its potential in the treatment of breast cancer
Martin, J., & Goldstein, L. J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s149245 · Cited by 42
“001).(22) Its approval was then expanded for use in conjunction with fulvestrant, based on results of the phase III PALOMA-3 trial in which patients were randomized to receive palbociclib/fulvestrant (N=347) or fulvestrant alone (N=174) following disease progression on nonsteroidal AI (PFS 9.”
BackgroundMechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
Zhang, J., Wang, Q., Wang, Q., Cao, J., Sun, J., & Zhu, Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03281-4 · Cited by 42
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
Zhao, J., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000710 · Cited by 42
“Several clinical trials have confirmed that it significantly improves PFS in patients with ER-positive advanced breast cancer.([90,91]) However, recent studies show that it can also promote anti-tumor immunity and increase tumor immunogenicity through the followingmechanism: First, CDK4/ 6 inhibitors enhance tumor ant…”
BackgroundSteenbruggen, T. G., Schaapveld, M., Horlings, H. M., Sanders, J., Hogewoning, S. J., Lips, E. H., Peeters, M.-J. T. F. D. V., Kok, N. F. M., Wiersma, T., Esserman, L. J., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab010 · Cited by 43
“Second, progress in systemic treatment options such as anti-HER2 therapies (25-30), immune-checkpoint inhibitors (31-33), and CDK4/6 inhibitors (34-36) has improved outcome of patients with MBC.”
BackgroundPan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma
Zhou, J. R., Wu, Z., Zhang, Z., Goss, L. B., McFarland, J. M., Nagaraja, A. K., Xie, Y., Gu, S. S., Peng, K., Zeng, Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323276 · Cited by 42
“25 26 One paper predicted CDKN2a or 2B loss as a potential biomarker for CDK4/6 inhibitor sensitivity.”
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
Wang, R., Xu, K., Gao, F., Huang, J., & Guan, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188590 · Cited by 44
Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer
Lau, T.-Y., & Kwan, H. Y. (2022) · Marine Drugs · doi:10.3390/md20060370 · Cited by 43
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhu, Z., Turner, N. C., Loi, S., André, F., Martín, M., Dieras, V. C., Gelmon, K. A., Harbeck, N., Zhang, C., Cao, J. Q., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00297-1 · Cited by 41
Self-citationSenkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34525 · Cited by 39
Self-citationBridging the Divide: A Review on the Implementation of Personalized Cancer Medicine
Masucci, M. M., Ernberg, I., Karlsson, C., & Blomqvist, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14060561 · Cited by 42
Jhaveri, K. L., Neven, P., Casalnuovo, M. L., Kim, S., Tokunaga, E., Aftimos, P., Saura, C., O’Shaughnessy, J., Harbeck, N., Carey, L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.11.018 · Cited by 49
Self-citationRole of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S., Vennepureddy, A., Dhar, V., Patibandla, P., & Sokoloff, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218770904 · Cited by 42
The Asian Breast Cancer Cooperative Group, Yeo, W., Ueno, T., Lin, C., Liu, Q., Lee, K.-H., Leung, R. C.-Y., Naito, Y., Park, Y. H., Im, S., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05318-5 · Cited by 41
Self-citationCersosimo, R. J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz121 · Cited by 42
Re, M. D., Crucitta, S., Lorenzini, G., Angelis, C. D., Diodati, L., Cavallero, D., Bargagna, I., Cinacchi, P., Fratini, B., Salvadori, B., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105241 · Cited by 42
Kaminska, K. K., Akrap, N., Staaf, J., Alves, C. L., Ehinger, A., Ebbesson, A., Hedenfalk, I. A., Beumers, L., Veerla, S., Harbst, K., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01402-1 · Cited by 39
“dences of cell cycle regulation as a strategy to enhance endocrine treatment activity [5, 6], we aimed to study whether there was a common cell cycle regulator that”
BackgroundFan, Y., Sun, T., Shao, Z., Zhang, Q., Ouyang, Q., Tong, Z., Wang, S., Luo, Y., Teng, Y., Wang, X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3428 · Cited by 44
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Doostan, I., Karakaş, C., Kohansal, M., Low, K.-H., Ellis, M. J., Olson, J. A., Suman, V. J., Hunt, K. K., Moulder, S., & Keyomarsi, K. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1544 · Cited by 38
“Randomized phase II (PALOMA-1) and III (PALOMA-2 and 3) clinical trials in patientswith advanced ERþbreast cancer reported doubling the progression-free survival with the addition of palbociclib to letrozole or fulvestrant alone (19, 20) One challenge of endocrine or CDK4/6 inhibitor therapy is identifying patients wh…”
BackgroundSelf-citationClinical development of CDK4/6 inhibitor for breast cancer
Iwata, H. (2018) · Breast Cancer · doi:10.1007/s12282-017-0827-3 · Cited by 39
Lee, C., Oh, P., Xu, E. S., Ma, Y., Kim, Y., Daniel, A. R., & Kirsch, D. G. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.07.192 · Cited by 41
“Blocking CDK4/6 does not alter radiosensitivity of human and mouse cancer cells in vitro.”
BackgroundInfluentialHsu, C.-L., Lui, K., Chi, L., Kuo, Y., Chao, Y., Yeh, C., Lee, L., Huang, Y., Lin, T., Huang, M.-Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0873-5 · Cited by 39
Thibault, S., Hu, W., Hirakawa, B. P., Kalabat, D. Y., Franks, T., Sung, T., Khoh‐Reiter, S., Lu, S., Finkelstein, M. B., Jessen, B. A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0734 · Cited by 38
“org Mol Cancer Ther; 18(2) February 2019 259”
BackgroundInfluentialNetworkER+, Cazzaniga, M. E., Danesi, R., Girmenia, C., Invernizzi, P., Elvevi, A., & Uguccioni, M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05261-5 · Cited by 44
Update on Precision Medicine in Breast Cancer
Sachdev, J. C., Sandoval, A. C., & Jahanzeb, M. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_2 · Cited by 39
Adamo, B., Bellet, M., Paré, L., Pascual, T., Vidal, M. J., Fidalgo, J. A. P., Blanch, S., Martínez-Jáñez, N., Murillo, L. S., Gómez-Pardo, P., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1195-z · Cited by 38
Biologic therapy for advanced breast cancer: recent advances and future directions
Tarantino, P., Morganti, S., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1752176 · Cited by 42
“The MONALEESA-2 [11,12], PALOMA-2 [13,14] and MONARCH-3 [15,16] trials, respectively, tested ribociclib, palbociclib, and abemaciclib in combination with AIs as first-line treatment for luminal BC.”
MethodGuerini, A. E., Pedretti, S., Salah, E., Simoncini, E., Maddalo, M., Pegurri, L., Pedersini, R., Vassalli, L., Pasinetti, N., Peretto, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70430-2 · Cited by 39
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
Recondo, G., Mahjoubi, L., Maillard, A., Loriot, Y., Bigot, L., Facchinetti, F., Bahleda, R., Gazzah, A., Hollebecque, A., Mezquita, L., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00130-7 · Cited by 40
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
Zheng, J., Yu, Y., Durairaj, C., Dieras, V. C., Finn, R. S., & Wang, D. D. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00771-5 · Cited by 38
Self-citationCurrent and emerging estrogen receptor-targeted therapies for the treatment of breast cancer
Haines, C., Wardell, S. E., & McDonnell, D. P. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200174 · Cited by 41
Li, Y., Li, W., Gong, C., Zheng, Y., Ouyang, Q., Xie, N., Qu, Q., Ge, R., & Wang, B. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211022890 · Cited by 41
Gao, J. J., Cheng, J., Prowell, T. M., Bloomquist, E. W., Tang, S. W., Wedam, S. B., Royce, M., Krol, D., Osgood, C. L., Ison, G., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00472-1 · Cited by 39
Ha, M. J., Raghavendra, A. S., Kettner, N. M., Qiao, W., Damodaran, S., Layman, R. M., Hunt, K. K., Shen, Y., Tripathy, D., & Keyomarsi, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.33959 · Cited by 39
“001).(10) OS data for PALOMA-2 remains maturing.”
Choi, B.-H., Rawat, V., Högström, J., Burns, P., Conger, K. O., Özgürses, M. E., Patel, J. M., Mehta, T. S., Warren, A., Selfors, L. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110278 · Cited by 44
“While the recent approvals of CDK4/6 and phosphatidylinositol 3-kinase (PI3K) inhibitors have improved the treatment of advanced luminal breast cancer, these therapies are still not curative for most patients (Andre et al., 2019; Finn et al., 2016; Goetz et al., 2017; Hortobagyi et al., 2018).”
Becherini, C., Visani, L., Caini, S., Bhattacharya, I. S., Kirby, A. M., Marta, G. N., Morgan, G., Salvestrini, V., Coles, C. E., Cortés, J., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102586 · Cited by 39
Self-citationToss, A., Venturelli, M., Peterle, C., Piacentini, F., Cascinu, S., & Cortesi, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010085 · Cited by 42
“These data of PFS improvement were then confirmed in the PALOMA 2 phase III study [86].”
ResultClassification of anticancer drugs: an update with FDA- and EMA-approved drugs
Ostios-García, L., Martínez-Pérez, D., Castelo, B., Herradón, N. H., Zamora, P. M., Feliú, J., & Espinosa, E. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10188-5 · Cited by 48
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis
Raphael, J., Helou, J. A., Pritchard, K. I., & Naimark, D. M. J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.018 · Cited by 37
Hadjadj, D., Kim, S.-J., Denecker, T., Driss, L. B., Cadoret, J., Maric, C. A., Baldacci, G., & Fauchereau, F. (2017) · Aging · doi:10.18632/aging.101356 · Cited by 39
“It has recently been approved in the United States of America and the European Union in these combinations [11–14].”
Masuda, N., Nishimura, R., Takahashi, M., Inoue, K., Ohno, S., Iwata, H., Mori, Y., Hashigaki, S., Muramatsu, Y., Nagasawa, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13507 · Cited by 37
“Median average duration of cycle delay, d (range) 7 (5-47) 7 (5-47)”
BackgroundWatson, G. A., Deac, O. M., Aslam, R., O’Dwyer, R., Tierney, A., Sukor, S., & Kennedy, J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.002 · Cited by 38
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Basudan, A., Priedigkeit, N., Hartmaier, R. J., Sokol, E. S., Bahreini, A., Watters, R. J., Boisen, M. M., Bhargava, R., Weiss, K. R., Karsten, M. M., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0946 · Cited by 40
Immunotherapy in pancreatic cancer: New hope or mission impossible?
Jiang, J., Zhou, H., Ni, C., Hu, X., Mou, Y., Huang, D., & Yang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.10.045 · Cited by 40
Therapeutic Options for Metastatic Breast Cancer
Sambi, M., Qorri, B., Harless, W. W., & Szewczuk, M. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_8 · Cited by 39
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Armaghani, A. J., & Han, H. S. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s219436 · Cited by 39
Galván-Morales, M. Á., Rodríguez, R. B., Cruz, J. R. S., & Teran, L. M. (2020) · Molecules · doi:10.3390/molecules25235686 · Cited by 42
“This goal will only be reached with further research, increasing the number of clinical trials, and obtaining the experience that will allow the future achievement of effective therapy against one of the diseases that cause many deaths in the world [148,159,160].”
Background
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.